Neoplasms

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Gland and Hormone Related Diseases

All Conditions

Immune System Diseases

Symptoms and General Pathology

Rare Diseases

Ovarian Neoplasms

Carcinoma, Ovarian Epithelial

Hypersensitivity

Carcinoma

Recurrence

Endocrine Gland Neoplasms

Ovarian Diseases

Adnexal Diseases

Genital Diseases, Female

Genital Diseases

Urogenital Diseases

Female Urogenital Diseases

Pregnancy Complications

Female Urogenital Diseases and Pregnancy Complications

Genital Neoplasms, Female

Urogenital Neoplasms

Endocrine System Diseases

Gonadal Disorders

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Disease Attributes

Ovarian Cancer

Ovarian Epithelial Cancer

Antineoplastic Agents

All Drugs and Chemicals

Anti-Infective Agents

Doxorubicin

Liposomal doxorubicin

Trabectedin

Anti-Bacterial Agents

Antibiotics, Antitubercular

Enzyme Inhibitors

Antineoplastic Agents, Alkylating

Alkylating Agents

Yondelis®-Caelyx®-relapse ovarian cancer

Observation of Yondelis®-Caelyx® administration

Yondelis®-Caelyx®

Frédéric SELLE, MD

The French cooperative group GINECO proposes to implement an observational study to describe a real situation, in daily practice tolerance and methods of administration of trabectedin (Yondelis®)-Pegylated liposomal doxorubicin(Caelyx)®, in ovarian platinum sensitive cancer relapse.

Population : Patients aged 18 years and older with an epithelial ovarian cancer, fallopian tube or primary peritoneal with platinum-sensitive recurrent witch it was decided to initiate a treatment with trabectedin (Yondelis®)-Pegylated liposomal doxorubicin(Caelyx)®.

Ovarian Cancer Treatment Platinum-sensitive Relapse - Cohort Study (PROSPECTYON)

Non Interventional Study Dealing With the Use of Trabectedin (Yondelis®)-Pegylated Liposomal Doxorubicin (Caelyx®) in Patient With Platinum-sensitive Relapse

To assess patient safety and the tolerance of Yondelis®-Caelyx® administered regarding the daily practice of the oncologist.

Describe the reason why treatment by trabectedin and doxorubicine combination was initiated (ex : number of patients with previous intolerance to platinum as allergic reaction, residual peripherical neuropathy, alopecia; availability of the combination yondelis-caelyx in the treating site; number of sites where the yondelis-caelyx combination is the reference treatment)

Describe the population that will be registered

Describe the way how treatment by Yondelis®-Caelyx® is administered in the daily practice for each patient (Initial dosage of caelyx and yondelis, number of cycles administered for each treatment , dose reductions occurence and reasons)

Evaluation of clinical benefit will be performed during the physical examination at baseline and during the treatment

At baseline : describe the number of patients how present the following related symptom disease : weight loss, ascites, abdominal pain, constipation, fatigue, occlusive syndrome

Then, describe the number of patients how presented and improvement or a degradation of theses related symptom disease during the treatment

Nota Bene : this cohort study is strictly observational and must represent the daily practice. No indications must be given regarding the frequency of the physical examination

Evaluate the efficacy of Yondelis®-Caelyx® in terms of progression-free survival (PFS), Overall Survival (OS), response to treatment.

PharmaMar

ARCAGY/ GINECO GROUP

Bevacizumab

Antineoplastic Agents, Immunological

Angiogenesis Inhibitors

Growth Inhibitors

Patient receiving bevacizumab in ovarian cancer first line treatment

Observation of bevacizumab administration in first line ovarian cancer treatment

Dominique BERTON-RIGAUD, MD

The French cooperative group GINECO proposes to implement an observational study to describe a real situation, in daily practice tolerance and methods of administration of bevacizumab (Avastin ®)

Population: Patients aged 18 years and older with an epithelial ovarian cancer, fallopian tube or primary peritoneal or witch it was decided to initiate a process comprising of Bevacizumab (Avastin ®) in first-line therapy

First Line Ovarian Cancer Treatment - Cohort Study

Non Interventional Study Dealing With the Use of Bevacizumab (Avastin®) in Patients With Epithelial Ovarian Cancer, Fallopian Tube or Primary Peritoneal and Treated in First-line Therapy

To assess patient safety and the tolerance of bevacizumab andministered regarding the daily practice of the oncologist.

• Evaluate the efficacy of bevacizumab (Avastin ®) in terms of progression-free survival (PFS) .

Evaluate the efficacy of the treatment that will be administered at the disease relapse.

Discribe the population that will be registered to make correlation with the safety and efficacy measure

Discribe the reason why patient receive or not bevacizumab in first line of ovarian cancer treatment

Discribe the method that are used during a treatment by bevacizumab in the daily practice

Discribe how bevacizumab is administered in the daily practice

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Ovarian Cancer Treatment Platinum-sensitive Relapse - Cohort Study (PROSPECTYON)	NCT02163720	Ovarian Cancer	Yondelis®-Caely...	18 Years -	ARCAGY/ GINECO GROUP
First Line Ovarian Cancer Treatment - Cohort Study	NCT01832415	Epithelial Ovar...	Bevacizumab	18 Years -	ARCAGY/ GINECO GROUP
First Line Ovarian Cancer Treatment - Cohort Study	NCT01832415	Epithelial Ovar...	Bevacizumab	18 Years -	ARCAGY/ GINECO GROUP

Spots Global Cancer Trial Database for fallopian tube or primary peritoneal